Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125763301 | 12576330 | 1 | I | 20160712 | 20160720 | 20160720 | EXP | US-GLAXOSMITHKLINE-US2016GSK103162 | GLAXOSMITHKLINE | TIMERMAN D, DEVLIN PM, NAMBUDIRI VE, WRIGHT NA, VLEUGELS RA, CLARK RA ET AL. NOVEL APPLICATION OF HIGH-DOSE RATE BRACHYTHERAPY FOR SEVERE, RECALCITRANT PALMOPLANTAR PUSTULOSIS. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2016;41:498-501 | 36.00 | YR | M | Y | 0.00000 | 20160720 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125763301 | 12576330 | 1 | PS | ACITRETIN. | ACITRETIN | 1 | U | 19821 | |||||||||||
| 125763301 | 12576330 | 2 | SS | Clobetasol | CLOBETASOL | 1 | U | 0 | OINTMENT | ||||||||||
| 125763301 | 12576330 | 3 | SS | METHOTREXATE. | METHOTREXATE | 1 | U | 0 | |||||||||||
| 125763301 | 12576330 | 4 | SS | Ciclosporin | CYCLOSPORINE | 1 | U | 0 | |||||||||||
| 125763301 | 12576330 | 5 | SS | DAPSONE. | DAPSONE | 1 | U | 0 | |||||||||||
| 125763301 | 12576330 | 6 | SS | ETANERCEPT | ETANERCEPT | 1 | U | 0 | |||||||||||
| 125763301 | 12576330 | 7 | SS | INFLIXIMAB | INFLIXIMAB | 1 | U | 0 | |||||||||||
| 125763301 | 12576330 | 8 | SS | ADALIMUMAB | ADALIMUMAB | 1 | U | 0 | |||||||||||
| 125763301 | 12576330 | 9 | SS | USTEKINUMAB | USTEKINUMAB | 1 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125763301 | 12576330 | 1 | Pustular psoriasis |
| 125763301 | 12576330 | 2 | Pustular psoriasis |
| 125763301 | 12576330 | 3 | Pustular psoriasis |
| 125763301 | 12576330 | 4 | Pustular psoriasis |
| 125763301 | 12576330 | 5 | Pustular psoriasis |
| 125763301 | 12576330 | 6 | Pustular psoriasis |
| 125763301 | 12576330 | 7 | Pustular psoriasis |
| 125763301 | 12576330 | 8 | Pustular psoriasis |
| 125763301 | 12576330 | 9 | Pustular psoriasis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125763301 | 12576330 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125763301 | 12576330 | Drug ineffective | |
| 125763301 | 12576330 | Drug resistance | |
| 125763301 | 12576330 | Treatment failure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |